Fierce Biotech Profiles Model Medicines’ “Creative Models” for AI Drug Discovery
Press Coverage
Patrick ONeill
Fierce Biotech profiles Model Medicines’ differentiated approach to AI drug discovery, highlighting how the company brings together data science, computer science, chemistry, biology, and drug development expertise to identify first-in-class therapeutic candidates.
Patrick ONeill
Head of Partnerships and Investor Relations
Fierce Biotech spotlighted Model Medicines’ mission to build a next-generation AI drug discovery company designed to move beyond conventional models and discover novel therapeutic opportunities. The article features insights from CEO Daniel Haders, Ph.D., on the company’s multidisciplinary team, its use of small but diverse training sets, and its focus on identifying outlier chemistry that could lead to breakthrough medicines.
“We create creative models.”
The feature also discusses Model Medicines’ virtual screening of 325 billion molecules, its oncology candidate MDL-4102, and its broad-spectrum antiviral candidate MDL-001 as examples of how the company is translating its AI-driven discovery approach into preclinical development programs.
Read the full article on Fierce Biotech: “Why Model Medicines needs to ‘discover new colors’ in its AI drug discovery quest”
